Abstract
Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, debilitating disease of unknown etiology and a median survival from diagnosis of 3-5 years. Despite extensive research efforts, its etiology in humans still remains largely unknown, and no curative drug therapies are available. With a gradually increasing worldwide incidence, IPF still presents a major challenge in clinical research due to its appreciable heterogeneity among individual patients in disease course and the lack of easily reproducible surrogate markers for patient relevant outcomes. Currently clinicians and researchers apply a panel of functional, radiological and histopathological indices to stratify patients into distinct phenotypic patterns of disease progression. However, none of these indicators can reliably predict not only treatment responsiveness but more importantly disease behavior, thus allowing clinicians to promptly apply aggressive therapeutic approaches to prevent or ameliorate acute exacerbation. Furthermore, on the contrary to molecular biomarkers, physiologic prognosticators provide no insights into disease mechanism and thus are unlikely to identify distinct molecular phenotypes of the disease. In the dawn of the “fibromics” era the need for disease stratification based on molecular phenotypes and implementation of personalized medicine therapeutic approaches is still unmet. Molecular biomarkers lie in the core of personalized medicine and therefore represent the main focus of this review article. Limitations that hamper their widespread clinical applicability along with future perspectives on how to address these major caveats and launch IPF biomarkers to the same trajectory as to tumor biomarkers in oncology are also discussed.
Keywords: Biomarkers, Idiopathic Pulmonary Fibrosis, Alveolar epithelial cell injury, Immunity, Extracellular matrix.
Current Topics in Medicinal Chemistry
Title:Biomarkers in the Evaluation and Management of Idiopathic Pulmonary Fibrosis
Volume: 16 Issue: 14
Author(s): Argyris Tzouvelekis, Jose Herazo-Maya, Koji Sakamoto and Demosthenes Bouros
Affiliation:
Keywords: Biomarkers, Idiopathic Pulmonary Fibrosis, Alveolar epithelial cell injury, Immunity, Extracellular matrix.
Abstract: Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, debilitating disease of unknown etiology and a median survival from diagnosis of 3-5 years. Despite extensive research efforts, its etiology in humans still remains largely unknown, and no curative drug therapies are available. With a gradually increasing worldwide incidence, IPF still presents a major challenge in clinical research due to its appreciable heterogeneity among individual patients in disease course and the lack of easily reproducible surrogate markers for patient relevant outcomes. Currently clinicians and researchers apply a panel of functional, radiological and histopathological indices to stratify patients into distinct phenotypic patterns of disease progression. However, none of these indicators can reliably predict not only treatment responsiveness but more importantly disease behavior, thus allowing clinicians to promptly apply aggressive therapeutic approaches to prevent or ameliorate acute exacerbation. Furthermore, on the contrary to molecular biomarkers, physiologic prognosticators provide no insights into disease mechanism and thus are unlikely to identify distinct molecular phenotypes of the disease. In the dawn of the “fibromics” era the need for disease stratification based on molecular phenotypes and implementation of personalized medicine therapeutic approaches is still unmet. Molecular biomarkers lie in the core of personalized medicine and therefore represent the main focus of this review article. Limitations that hamper their widespread clinical applicability along with future perspectives on how to address these major caveats and launch IPF biomarkers to the same trajectory as to tumor biomarkers in oncology are also discussed.
Export Options
About this article
Cite this article as:
Tzouvelekis Argyris, Herazo-Maya Jose, Sakamoto Koji and Bouros Demosthenes, Biomarkers in the Evaluation and Management of Idiopathic Pulmonary Fibrosis, Current Topics in Medicinal Chemistry 2016; 16 (14) . https://dx.doi.org/10.2174/1568026616666150930120959
DOI https://dx.doi.org/10.2174/1568026616666150930120959 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Physicochemical Characterization and Evaluation of Buccal Adhesive Patches Containing Propranolol Hydrochloride
Current Drug Delivery Hypertension, Cognitive Impairment and Dementia: An Epidemiological Perspective
Current Hypertension Reviews Current Perspectives on Anti-Aging Interventions
Letters in Drug Design & Discovery Sesamol Induces Apoptosis by Altering Expression of Bcl-2 and Bax Proteins and Modifies Skin Tumor Development in Balb/c Mice
Anti-Cancer Agents in Medicinal Chemistry Naringenin and Atherosclerosis: A Review of Literature
Current Pharmaceutical Biotechnology Targeting Angiogenesis in Ovarian Carcinoma
Current Cancer Therapy Reviews Enkephalin Degrading Enzymes: Metalloproteases with High Potential for Drug Development
Current Pharmaceutical Design Latest Advances in Breast Sonography
Recent Patents on Medical Imaging Nephrotoxicity Associated with Antiretroviral Therapy in HIV-Infected Patients
Current Drug Safety Hypertension and Diabetes: Emphasis on the Renin-Angiotensin System in Atherosclerosis
Current Hypertension Reviews Creatine and the Liver: Metabolism and Possible Interactions
Mini-Reviews in Medicinal Chemistry Current Status of Renal Artery Angioplasty and Stenting for Resistant Hypertension: A Case Series and Review of the Literature
Current Hypertension Reviews Smoking and Hypertension: Independent or Additive Effects to Determining Vascular Damage?
Current Vascular Pharmacology Chromogranin A in Tumors: More Than a Marker for Diagnosis and Prognosis
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Microbiome Regulation of Autoimmune, Gut and Liver Associated Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Food Applications for Flaxseed and its Components: Products and Processing
Recent Patents on Food, Nutrition & Agriculture Antenatal Hypoxia and Pulmonary Vascular Function and Remodeling
Current Vascular Pharmacology Effect of Depression on Self-Management Behaviors and Health Outcomes in Adults with Type 2 Diabetes
Current Diabetes Reviews Pulmonary Hypertension in Cardiac Surgery
Current Cardiology Reviews The Role of Pericytes in Blood-Brain Barrier Function and Stroke
Current Pharmaceutical Design